OakChart

Zevra Therapeutics Inc

ZVRAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

11.85-0.07 (-0.59%)
2026-11-12 05:39 CET
Market cap
705.13 USD m
Revenue, TTM
147.76 USD m
Net income, TTM
74.96 USD m
Free cash flow, TTM
38.28 USD m
EPS diluted, TTM
1.20
P/E
9.91
Compare

Price

ZVRA against its 20, 50 and 200-day averages
2050200beatearnings
10.0012.0014.003.5M6.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ZVRAclose 11.8520-day 10.5750-day 11.08200-day 10.8311.8552w high

21.2% under the 52-week high of 15.04 on 8 Jul 2026. 52-week low 8.01 on 19 Dec 2025. Last 15 sessions, 29.0% high to low

Volume 0.82× normal · the line is the 50-bar volume average

Profile

ZVRA
52-week range, 55% of the way up
8.0115.03

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

IndexRUT
Employees61
IPOApr 16, 2015
Beta0.97
ATR, 14d0.55
Rel volume0.82
Short float11.18%
Insider own1.46%
Inst own80.36%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap705.13M
Enterprise Value510.79M
Income74.96M
Sales147.76M
Book/sh4.02
Cash/sh3.29
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees61
IPOApr 16, 2015

Ratios

P/E9.91
Forward P/E12.74
PEG5.95
P/S4.77
P/B2.95
P/C3.61
P/FCF18.42
EV/EBITDA10.67
EV/Sales3.46
Quick Ratio5.38
Current Ratio5.46
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)1.20
EPS next Y0.93
EPS next Q0.19
EPS this Y-6.58%
EPS next Y-26.26%
EPS next 5Y2.14%
EPS past 3/5Y- -
Sales past 3/5Y118.82% 51.62%
EPS Y/Y TTM103.22%
Sales Y/Y TTM75.10%
EPS Q/Q2767.01%
Sales Q/Q44.86%
EarningsNov 03 AMC
EPS/Sales Surpr.64.97% 1.82%

Ownership

Insider Own1.46%
Insider Trans-11.36%
Inst Own80.36%
Inst Trans6.66%
ROA25.69%
ROE40.29%
ROIC31.30%
Gross Margin94.52%
Oper. Margin31.47%
Profit Margin50.73%
SMA2012.09%
SMA506.97%
SMA2009.38%
Trades-

Technical

Shs Outstand59.44M
Shs Float58.63M
Short Float11.18%
Short Ratio7.23
Short Interest6.56M
52W High15.03 -21.18%
52W Low8.01 47.94%
Volatility6.35% 4.81%
ATR (14)0.55
RSI (14)60.56
Beta0.97
Rel Volume0.82
Avg Volume907.31K
Volume743,621

Performance

Perf Week6.09%
Perf Month14.05%
Perf Quarter5.99%
Perf Half Y6.56%
Perf YTD32.25%
Perf Year25.66%
Perf 3Y185.54%
Perf 5Y26.60%
Perf 10Y-81.71%
Recom1.00
Target Price25.25
Prev Close11.92
Price11.85
Change %-0.59%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Mar 16, 2026InitiatedBBTIG ResearchBuy$23+94.1%
Jul 02, 2025InitiatedHH.C. WainwrightBuy$26+119.4%
Jan 08, 2025ResumedCCantor FitzgeraldOverweight$25+111.0%
Oct 07, 2024InitiatedGGuggenheimBuy$20+68.8%
Sep 24, 2024ReiteratedMMaxim GroupBuy$18 → $25+111.0%
Sep 24, 2024InitiatedJJMP SecuritiesMkt Outperform$17+43.5%
Apr 02, 2024ReiteratedMMaxim GroupBuy$12 → $18+51.9%
Mar 12, 2024InitiatedWWilliam BlairOutperform
Mar 17, 2023InitiatedMMaxim GroupBuy$12+1.3%

Peers

Mkt cap
TickerCompanyMkt cap
RAREUltragenyx Pharmaceutical Inc1.70B
MIRMMirum Pharmaceuticals Inc6.18B
PTCTPTC Therapeutics Inc5.42B
HRMYHarmony Biosciences Holdings Inc2.01B
TVTXTravere Therapeutics Inc5.00B
AGIOAgios Pharmaceuticals Inc1.96B
BMRNBiomarin Pharmaceutical Inc11.30B
ETONEton Pharmaceuticals Inc1.97B
DNLIDenali Therapeutics Inc3.16B
BBIOBridgeBio Pharma Inc15.49B

Insider trading

latest 14 of 27
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
McFarlane Neil F.President and CEOOct 12 '26Sale11.2520,000224,948417,225Oct 13 04:24 PM
NEIL F MCFARLANEDirectorOct 12 '26Proposed Sale11.3920,000227,800Oct 13 08:22 AM
Thompson RahsaanChief Legal & ComplianceAug 14 '26Sale11.1342,666474,77437,569Aug 17 04:32 PM
RAHSAAN THOMPSONOfficerAug 14 '26Proposed Sale11.1842,666477,006Aug 14 04:31 PM
Watton Corey MichaelDirectorAug 10 '26Option Exercise4.9712,30061,13114,100Aug 12 04:16 PM
Watton Corey MichaelDirectorAug 10 '26Sale11.2512,300138,3771,800Aug 12 04:16 PM
JOHN BODEDirectorJul 08 '26Proposed Sale14.8510,516156,163Jul 08 04:01 PM
Thompson RahsaanChief Legal & ComplianceJun 22 '26Sale12.6834,557438,30480,235Jun 23 04:16 PM
Thompson RahsaanChief Legal & ComplianceMay 11 '26Sale11.301,79420,27248,125May 13 04:32 PM
Rahsaan ThompsonOfficerMay 11 '26Proposed Sale11.1336,351404,587May 11 04:34 PM
Bode John BDirectorMar 24 '26Option Exercise4.9378,400386,512123,400Mar 26 08:27 AM
RAYMOND L CLIFTONOfficerMar 16 '26Proposed Sale9.87345,4283,409,374Mar 16 04:45 PM
McFarlane Neil F.President and CEOFeb 09 '26Sale8.5614,625125,186387,225Feb 10 04:49 PM
Sangiovanni Timothy J.SVP, Finance & Corp ControllerFeb 03 '26Sale9.183,00027,54829,590Feb 04 04:27 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
JSMDJanus Henderson Small/Mid Cap Growth Alpha ETFAUM: 1.04B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
JSMLJanus Henderson Small Cap Growth Alpha ETFAUM: 377.91M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-030.2600.1580.26037.7637.089
2026Q22026-08-050.1400.1100.13739.6633.889
2026Q12026-05-060.6000.0810.60336.2231.969
2025Q42026-03-090.1900.0500.19734.1028.058
2025Q32025-11-05-0.010-0.034-0.01026.0626.638
2025Q22025-08-121.2102.2641.36425.8822.565
2025Q12025-05-13-0.060-0.181-0.05720.4016.917
2024Q42025-03-11-0.670-0.395-0.66612.008.938
2024Q32024-11-12-0.690-0.412-0.6953.704.878
2024Q22024-08-13-0.480-0.454-0.4764.454.375
2024Q12024-05-08-0.400-0.467-0.3983.433.766
2023Q42024-03-28-0.510-0.268-0.40013.2011.736
2023Q32023-11-07-0.400-0.298-0.4052.903.384
2023Q22023-08-14-0.150-0.310-0.1508.473.074
2023Q12023-05-15-0.340-0.233-0.3412.882.664
2022Q42023-03-07-0.260-0.185-0.2612.303.114

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-13.280-11.360-13.23112.8416.98
2020FY-3.210-2.750-3.20513.2912.88
2021FY-2.110-0.855-2.11428.6528.30
2022FY-1.200-1.115-0.77610.4611.24
2023FY-1.300-1.183-1.29927.4625.98
2024FY-2.280-1.894-2.28123.6120.51
2025FY1.3501.2501.350106.47100.38
2026FY-1.261--153.57
2027FY-0.930--179.34
2028FY-1.439--224.87
2029FY-1.933--267.26
2030FY-2.459--316.16

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0493340.0837.3043.26
2026Q4S2026-11-0390039.5737.3041.90
2026Q4S2026-10-2090039.5737.3041.90
2026Q4S2026-10-1293239.5737.3041.90
2026Q4S2026-08-2493239.5737.3041.90
2026Q4S2026-08-1993339.5737.3041.90
2026Q4S2026-08-1193439.5737.3041.90
2026Q4S2026-08-1093439.5637.2841.90
2026Q4S2026-08-0693439.5737.3041.90
2026Q4S2026-07-2491239.7235.5046.30
2026Q4S2026-07-2391239.7235.5046.30
2026Q4S2026-07-2191239.7135.5046.00
2026Q4S2026-07-2093639.7135.5046.00
2026Q4S2026-07-1093639.7435.5046.30

Estimate history

EPS, annual-47.36-50.388-13.231-3.205-2.114-0.776-1.299-2.2811.3551.1954
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.695-0.666-0.0571.364-0.010.1970.6030.1370.259
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0012.83913.28828.6510.16127.46123.612106.47147.76
Period201720182019202020212022202320242025TTM
Sales, quarterly3.69512.04320.40125.88126.06334.12536.2239.66337.756
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.9161.6532.2724.53735.00635.4541.53553.67156.85559.44
Period201720182019202020212022202320242025MRQ
Shares, quarterly53.22753.67154.67955.08456.21856.85559.11559.34259.44
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue147.76106.4723.6127.4610.1628.6513.2912.840.00
Cost of Goods Sold Incl. D&A8.1020.5420.043.951.172.321.583.250.32
Gross Profit139.6785.933.5723.518.9926.3311.719.59-0.32
Selling, General and Administrative Excl. Other93.1690.1790.5773.1133.9018.6116.4929.9353.94
Research and Development16.3412.5535.7138.8018.869.908.5719.1141.76
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income46.50-4.23-87.00-49.60-24.907.73-4.78-20.34-54.27
Interest Expense3.667.987.351.500.340.387.096.517.09
Unusual Expense7.0856.38-2.04-0.523.0816.121.01-2.00-4.34
Net Income Before Taxes89.9886.68-90.14-46.05-26.80-8.52-12.79-24.54-56.59
Income Taxes11.973.4515.370.00-0.030.03-0.03-0.02-0.13
Consolidated Net Income74.9677.58-105.51-46.05-26.77-8.55-12.76-24.52-56.47
Net Income From Continuing Operations74.9677.58-105.51-46.05-26.77-8.55-12.76-24.52-56.47
Net Income74.9677.58-105.51-46.05-26.77-62.90-12.76-24.52-56.47
EPS (Recurring)1.252.04-2.31-1.31-0.71-1.73-3.03-13.99-53.10
EPS (Basic, Before Extraordinaries)1.281.40-2.28-1.30-0.78-2.11-3.21-13.23-50.39
EPS (Diluted)1.201.35-2.28-1.30-0.78-2.11-3.21-13.23-50.39
EBITDA47.87-0.18-80.61-48.60-23.967.99-4.51-20.03-53.94
Non-Operating Income (Expense)54.21155.272.174.541.510.250.090.310.42
Other After Tax Adjustments-3.05-5.640.000.000.000.000.000.000.00
Stock Option Compensation Expense10.299.9811.784.703.391.781.823.225.13
Price To Earnings Ratio9.919.91-------
Price To Sales Ratio4.584.8216.348.4615.589.053.360.88-
Gross Margin94.5280.7115.1285.6188.5291.9288.1274.69-
Operating Margin31.47-3.98-368.47-180.63-245.0726.98-35.98-158.40-
Net Margin50.7372.87-446.85-167.69-263.48-219.54-96.03-191.00-
Shares Outstanding59.4456.8553.6741.5335.4535.014.542.271.65
Market Capitalization705.13705.13445.15271.73158.38307.6350.8113.7947.09

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue37.7639.6636.2234.1226.0625.8820.4012.04
Cost of Goods Sold Incl. D&A2.111.842.271.881.5513.992.964.63
Gross Profit35.6537.8233.9532.2424.5111.8917.447.41
Selling, General and Administrative Excl. Other24.0721.0525.1222.9320.3724.2122.8022.83
Research and Development4.944.494.342.573.433.433.266.70
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income11.5816.788.839.314.14-12.33-5.36-15.42
Interest Expense0.000.001.711.952.052.011.972.19
Unusual Expense-5.106.559.22-3.595.3859.46-4.872.69
Net Income Before Taxes19.7212.7944.8012.67-0.9876.91-1.92-20.37
Income Taxes0.514.046.910.50-0.432.201.1815.37
Consolidated Net Income18.428.3936.3211.83-0.5474.71-3.10-35.74
Net Income From Continuing Operations18.428.3936.3211.83-0.5474.71-3.10-35.74
Net Income18.428.3936.3211.83-0.5474.71-3.10-35.74
EPS (Recurring)0.200.210.710.160.062.12-0.12-0.63
EPS (Basic, Before Extraordinaries)0.310.140.620.21-0.011.36-0.06-0.67
EPS (Diluted)0.260.140.600.20-0.011.36-0.06-0.67
EBITDA11.9017.099.209.684.54-10.68-3.71-13.77
Non-Operating Income (Expense)3.032.5646.901.712.31150.700.54-0.07
Other After Tax Adjustments-0.78-0.36-1.57-0.340.000.000.000.00
Stock Option Compensation Expense2.112.352.453.382.192.462.463.17
Price To Earnings Ratio9.916.666.2414.20----
Price To Sales Ratio4.586.464.595.066.317.789.9818.96
Gross Margin94.4195.3693.7594.4894.0445.9385.4961.55
Operating Margin30.6742.3024.3827.3015.90-47.64-26.28-128.01
Net Margin48.8021.16100.2734.67-2.09288.66-15.19-296.76
Shares Outstanding59.4459.3459.1156.8556.2255.0854.6853.67
Market Capitalization705.13847.71547.19504.43533.84481.73405.33445.15

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments191.0169.5043.0565.95112.354.323.2221.6743.33
Short Term Receivables23.2610.5117.388.301.532.581.860.142.08
Inventories1.741.970.000.000.000.000.000.000.00
Other Current Assets7.004.0526.5118.591.181.480.751.911.59
Total Current Assets223.0186.0386.9492.83115.068.385.8323.7247.00
Net Property, Plant & Equipment1.701.011.531.782.022.393.011.752.00
Total Investments and Advances47.886.010.0020.0015.420.000.340.713.25
Long-Term Note Receivable----0.40----
Intangible Assets11.1273.6973.930.00----0.00
Other Assets1.0211.389.940.720.040.441.330.560.21
Total Assets284.73178.13172.33115.34132.9411.2110.5126.7552.46
Short Term Debt Incl. Current Port. of LT Debt0.420.4238.240.490.370.890.523.553.52
Accounts Payable2.4813.0713.993.610.521.171.143.712.18
Income Tax Payable13.71--------
Other Current Liabilities22.6720.5721.497.933.345.473.774.745.81
Total Current Liabilities39.2834.0673.7212.024.237.545.4312.0011.51
Long Term Debt62.7959.885.5213.641.2469.6679.4178.5089.96
Provision for Risks Charges9.697.667.664.330.000.000.000.000.00
Other Liabilities18.3236.8723.5610.230.350.430.122.818.50
Total Liabilities130.07138.46110.4640.225.8277.6284.9693.31109.97
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity154.6639.6761.8675.12127.12-66.41-74.46-66.57-57.52
Total Shareholders Equity154.6639.6761.8675.12127.12-66.41-74.46-66.57-57.52
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity154.6639.6761.8675.12127.12-66.41-74.46-66.57-57.52
Total Liabilities & Stockholders Equity284.73178.13172.33115.34132.9411.2110.5126.7552.46
Book Value Per Share2.720.741.492.123.63-14.64-32.77-40.26-62.78
Tangible Book Value Per Share2.52-0.63-0.292.123.63-14.64-32.77-40.26-62.78
Full-Time Employees615969362422223332
Price to Book Ratio2.956.363.521.692.40-0.77-0.19-0.71-1.23
Return on Assets33.52-60.21-31.99-21.57-11.87-117.52-131.65-142.59-63.18
Return on Equity79.85-207.84-62.37-26.48-28.19----
Return on Invested Capital35.68-106.00-68.34-30.16-6.67-393.10-494.79-473.11-133.73
Quick Ratio5.632.471.187.7227.201.111.071.984.08
Current Ratio5.682.531.187.7227.201.111.071.984.08

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income78.0283.23-105.51-46.05-26.77-8.55-12.76-24.52-56.47
Depreciation1.474.056.391.010.940.260.270.300.32
Other Funds (Non Cash)-34.97-62.3736.105.627.5216.2110.175.604.04
Funds from Operations44.5224.91-63.02-39.42-18.317.92-2.31-18.62-52.10
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.78-26.51-6.645.88-0.41-0.360.37-5.12-2.29
Cash from Operating Activities38.74-1.60-69.67-33.53-18.727.56-1.94-23.74-54.39
Capital Expenditures-0.46-0.830.00-0.30-0.09-0.10-0.03-0.03-0.02
Net Assets From Acquisitions0.000.000.00-30.40-14.090.000.000.00-
Sale of Fixed Assets and Businesses149.86150.450.000.000.000.000.000.00-
Purchase or Sale of Investments28.11-131.49-16.1613.31-22.54-15.420.003.2633.35
Purchase of Investments-247.61-309.99-41.16-45.81-23.86-15.420.000.000.00
Sale Or Maturity of Investments275.72178.5025.0059.121.320.000.003.2633.35
Other Uses0.000.00-6.000.000.000.000.000.000.00
Other Sources-101.060.000.000.000.000.000.000.000.00
Cash from Investing Activities76.4418.13-22.16-17.39-36.72-15.52-0.033.2333.33
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock14.4812.4467.262.88-4.4075.95-0.080.0028.40
Repurchase of Common Pref Stock0.000.000.00-3.45-4.72-2.810.000.000.00
Sale of Common Pref Stock14.4812.4467.266.320.3278.77-0.080.0028.40
Proceedsfrom Stock Options-0.828.6464.526.320.3247.95-0.080.0028.33
Issuance or Reduction of Debt, Net-60.090.0014.2024.8912.78-38.102.824.94-0.19
Change in Long Term Debt-60.090.0014.2024.8912.78-38.102.824.94-0.19
Issuance of Long Term Debt0.000.0056.9042.4312.800.003.055.150.00
Reduction of Long Term Debt-60.090.00-42.70-17.54-0.02-38.10-0.23-0.21-0.19
Net Financing Active Other Cash Flow-1.51-0.370.650.69-0.0378.140.000.000.00
Other Financing Activities Uses-1.51-0.37-0.43-0.56-1.310.000.000.000.00
Cash from Financing Activities-47.1212.0682.1128.468.35115.992.744.9428.20
Exchange Rate Effect-0.350.030.450.040.20----
Net Change in Cash67.7128.62-9.26-22.42-46.88108.020.77-15.567.15
Free Cash Flow38.28-2.43-69.67-33.83-18.817.46-1.97-23.76-54.41
Preferred Dividends (Cash Flow)-0.000.000.000.00-0.000.000.00
Price to Free Cash Flow17.69----34.77---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments195.57221.57200.62191.01199.51202.61
Short Term Receivables19.9422.4922.1023.2616.8418.27
Inventories3.072.452.311.741.371.11
Other Current Assets7.264.794.947.007.404.35
Total Current Assets225.84251.30229.97223.01225.12226.34
Net Property, Plant & Equipment2.242.311.521.701.822.10
Total Investments and Advances75.3238.6136.1547.8830.8615.09
Intangible Assets10.1810.4910.8111.1211.4411.75
Other Assets0.000.000.141.020.871.00
Total Assets313.57302.71278.58284.73270.12256.28
Short Term Debt Incl. Current Port. of LT Debt0.630.630.410.420.440.53
Accounts Payable13.6713.9611.6911.6011.0715.84
Income Tax Payable18.5320.8420.3513.71--
Other Current Liabilities8.5413.2014.5813.5514.6012.46
Total Current Liabilities41.3748.6347.0339.2826.1128.83
Long Term Debt0.600.870.7462.7962.2861.75
Provision for Risks Charges14.7913.109.489.6913.3411.86
Other Liabilities17.8922.4615.5318.3235.2336.60
Total Liabilities74.6585.0672.78130.07136.95139.05
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity238.92217.65205.80154.66133.16117.23
Total Shareholders Equity238.92217.65205.80154.66133.16117.23
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity238.92217.65205.80154.66133.16117.23
Total Liabilities & Stockholders Equity313.57302.71278.58284.73270.12256.28
Book Value Per Share4.023.673.482.722.372.13
Tangible Book Value Per Share3.853.493.302.522.171.91
Full-Time Employees---61--
Price to Book Ratio2.954.123.433.784.4711.74
Return on Assets25.6920.0354.2035.8215.301.32
Return on Equity40.2933.4499.1185.3234.813.53
Return on Invested Capital7.693.8417.585.44-0.2841.74
Quick Ratio5.385.124.845.638.577.81
Current Ratio5.465.174.895.688.627.85

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income19.218.7537.8912.16-0.5474.71
Depreciation0.380.360.370.360.391.65
Other Funds (Non Cash)-5.158.84-41.703.047.19-72.67
Funds from Operations14.4417.96-3.4415.577.043.69
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.39-0.939.59-10.05-2.33-7.29
Cash from Operating Activities10.0517.036.145.524.71-3.60
Capital Expenditures-0.24-0.22-0.040.03-0.55-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.00-0.040.04149.860.590.00
Purchase or Sale of Investments-34.6126.7135.680.34-4.61-137.85
Purchase of Investments-79.61-22.54-58.30-87.16-65.11-150.35
Sale Or Maturity of Investments45.0049.2593.9787.5060.5012.50
Other Uses0.000.000.000.000.000.00
Other Sources0.005.0043.94-150.000.00150.00
Cash from Investing Activities-34.8531.4579.620.23-4.5811.93
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.580.439.922.556.531.38
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.580.439.922.556.531.38
Proceedsfrom Stock Options0.000.430.00-1.259.480.41
Issuance or Reduction of Debt, Net0.000.00-60.090.000.000.00
Change in Long Term Debt0.000.00-60.090.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-60.090.000.000.00
Net Financing Active Other Cash Flow-0.031.15-2.630.000.000.00
Other Financing Activities Uses-0.031.15-2.630.000.000.00
Cash from Financing Activities1.551.58-52.802.556.531.38
Exchange Rate Effect0.08-0.340.23-0.320.060.66
Net Change in Cash-23.1749.7333.197.976.7310.37
Free Cash Flow9.8116.826.115.554.16-3.81
Price to Free Cash Flow17.6926.9646.80---

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 23.61M 2025: 106.47M
United States2024: 23.61M 2025: 106.47M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.18%6.6M58.6M903.96K
2026-10-1510.64%6.2M58.5M1.07M
2026-09-3012.19%7.1M58.6M1.16M
2026-09-159.79%5.7M58.6M1.25M
2026-08-319.85%5.8M58.6M1.49M
2026-08-1411.04%6.5M58.6M1.72M
2026-07-3112.17%7.1M58.6M1.82M
2026-07-1513.37%7.8M58.3M1.68M
2026-06-3011.13%6.5M58.3M1.54M
2026-06-1511.17%6.5M58.4M1.44M
2026-05-2910.22%6.0M58.4M1.40M
2026-05-157.61%4.4M58.4M1.18M
2026-04-308.55%5.0M58.3M1.00M
2026-04-158.20%4.8M58.3M1.03M
2026-03-317.67%4.4M57.9M1.10M
2026-03-138.15%4.7M57.9M1.10M
2026-02-279.75%5.4M55.5M903.22K
2026-02-138.93%5.0M55.5M1.03M
2026-01-308.64%4.8M55.6M1.21M
2026-01-157.16%4.0M55.8M1.23M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.007.9012.008.590.0005.000.000.991-0.0160.000
call3.006.9011.000.0018.3440.000.000.987-0.0160.001
call4.005.9010.000.0013.6430.000.000.984-0.0160.001
call5.004.909.006.3510.97149.000.000.980-0.0160.001
call6.003.908.000.009.0960.000.000.975-0.0160.001
call7.002.957.004.107.6434.000.000.969-0.0150.001
call8.001.955.203.004.82725.000.000.960-0.0150.002
call9.001.004.902.275.2357.000.000.948-0.0140.002
call10.000.154.002.014.4957310.000.724-0.1610.006
call11.000.103.100.753.7915440.000.663-0.1430.007
call12.000.051.000.351.4461,3272.000.561-0.0980.007
call13.000.050.200.090.7882491760.262-0.0290.006
call14.000.000.500.101.11122016.000.192-0.0320.005
call15.000.000.400.051.38457.000.000.163-0.0360.005
call16.000.002.150.001.6230.000.000.145-0.0390.004
call17.000.002.150.001.8370.000.000.132-0.0410.004
call18.000.002.000.002.0320.000.000.123-0.0430.004
call19.000.002.150.002.2110.000.000.115-0.0450.004
call20.000.002.150.002.0360.000.000.068-0.0280.002
call21.000.002.150.002.5290.000.000.105-0.0480.003
call22.000.002.150.002.6720.000.000.101-0.0490.003
call23.000.002.150.002.7210.000.000.097-0.0490.003
call24.000.002.150.002.9340.000.000.094-0.0510.003
call25.000.002.150.253.0547.000.000.091-0.0520.003
call26.000.002.150.002.7660.000.000.054-0.0320.002
call27.000.002.150.003.2750.000.000.087-0.0540.003
put2.000.002.150.056.0781.000.00-0.009-0.0160.000
put3.000.002.150.004.7310.000.00-0.013-0.0160.001
put4.000.002.150.003.7880.000.00-0.016-0.0160.001
put5.000.002.150.003.0670.000.00-0.020-0.0160.001
put6.000.002.150.005.4230.000.00-0.107-0.1040.003
put7.000.002.150.051.98512.000.00-0.031-0.0150.001
put8.000.001.500.251.54967.000.00-0.040-0.0140.002
put9.000.002.150.051.1561080.00-0.052-0.0130.002
put10.000.002.200.304.59236.000.00-0.276-0.1590.006
put11.000.002.200.253.73327.000.00-0.337-0.1420.007
put12.000.002.650.583.532394168-0.439-0.0970.007
put13.000.103.102.273.26874.000.00-0.738-0.0270.006
put14.000.204.101.833.68513.000.00-0.808-0.0300.005
put15.001.055.100.004.0440.000.00-0.837-0.0340.005
put16.002.056.100.004.3600.000.00-0.855-0.0370.004
put17.003.007.100.004.6430.000.00-0.868-0.0390.004
put18.004.008.100.004.9000.000.00-0.877-0.0410.004
put19.005.009.100.005.1340.000.00-0.885-0.0430.004
put20.006.0010.100.005.3500.000.00-0.890-0.0440.003
put21.007.0011.100.005.5500.000.00-0.895-0.0460.003
put22.008.0012.100.005.7360.000.00-0.899-0.0470.003
put23.009.0013.100.005.9100.000.00-0.903-0.0480.003
put24.0010.0014.100.006.0740.000.00-0.906-0.0490.003
put25.0011.0015.100.006.2280.000.00-0.909-0.0500.003
put26.0012.0016.100.006.3740.000.00-0.911-0.0500.003
put27.0013.0017.100.006.5120.000.00-0.913-0.0510.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-10SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13GSEC
2026-07-08144Filing for proposed sale of securities under Rule 144.SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-21SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-058-KCurrent report2026-06-04SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-11144Filing for proposed sale of securities under Rule 144.SEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-05-06SCHEDULE 13GSEC
2026-04-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-04SEC
2026-04-06PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000224.95K1
2026-090000
2026-0800613.15K2
2026-070000
2026-0600438.30K1
2026-050020.27K1
2026-040000
2026-030000
2026-02001.10M4
2026-0100121.29K4
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC9.37%
BlackRock, Inc.8.64%
Woodline Partners LP8.10%
Nantahala Capital Management, LLC6.08%
VANGUARD CAPITAL MANAGEMENT LLC4.46%
STATE STREET CORP2.85%
GEODE CAPITAL MANAGEMENT, LLC2.62%
D. E. Shaw & Co., Inc.2.21%
Qube Research & Technologies Ltd2.10%
MORGAN STANLEY2.04%

Funds

Fund% owned
Fidelity Contrafund4.98%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.21%
iShares Russell 2000 ETF2.58%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Janus Henderson Small/Mid Cap Growth Alpha ETF1.13%
Fidelity Small Cap Index Fund1.09%
Fidelity Contrafund K61.07%
iShares Biotechnology ETF0.70%
iShares Russell 2000 Value ETF0.64%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF0.62%

OakChart. ZVRA. Cached 15 minutes.